Clinzerv Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 5 Year, 7 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 87.25%
- Profit Growth 1885.11%
- Ebitda 2104.64%
- Net Worth 79.47%
- Total Assets 49.19%
About Clinzerv Pharmaceuticals
Clinzerv Pharmaceuticals Private Limited (CPPL) is a Private Limited Indian Non-Government Company incorporated in India on 05 July 2019 (Five years and seven months 12 days old ). Its registered office is in Delhi, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Mohammad Rajput and Mohd Rajput serve as directors at the Company.
Company Details
-
Location
Delhi, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U24239DL2019PTC352281
-
Company No.
352281
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
05 Jul 2019
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at Clinzerv Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Mohammad Rajput
|
Director | 05-Jul-2019 | Current |
|
Mohd Rajput
|
Director | 05-Jul-2019 | Current |
Financial Performance of Clinzerv Pharmaceuticals.
Clinzerv Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 87.25% increase. The company also saw a substantial improvement in profitability, with a 1885.11% increase in profit. The company's net worth Soared by an impressive increase of 79.47%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Clinzerv Pharmaceuticals?
In 2023, Clinzerv Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Evolvia Healthcare Services Private LimitedMohammad Rajput is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Clinzerv Pharmaceuticals?
Unlock and access historical data on people associated with Clinzerv Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Clinzerv Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Clinzerv Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
